期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 19, 期 33, 页码 5575-5580出版社
BAISHIDENG PUBL GRP CO LTD
DOI: 10.3748/wjg.v19.i33.5575
关键词
Lactic acidosis/hyperlactatemia; Telbivudine; Hepatitis B virus; Nucleoside analogue; Adverse effects
资金
- National Natural Science Foundation of China [81071354, 81271833]
- National 973'' Project [2012CB519001]
- National Science and Technology Major Project of China [2012ZX10002007-001-002, 2013ZX10002001]
All oral nucleoside analogues against hepatitis B virus, with an exception of telbivudine, have been reported causing lactic acidosis (LA). Here we report the first case of chronic hepatitis B developing severe refractory LA during telbivudine monotherapy. A 36-year-old man of Chinese origin received telbivudine antiviral treatment for chronic hepatitis B. After 11 mo of therapy, he developed anorexia, nausea, and vomiting with mild muscle weakness. The patient was found with elevated serum creatine phosphokinase up to 3683 U/L (upper limit of normal 170 U/L) and marked LA. LA did not resolve immediately following discontinuation of telbivudine. His condition began to improve after hemodialysis treatment for 16 times and usage of glucocorticosteroid. The patient fully recovered after 16 wk of treatment. This is the first documented case with severe LA caused by telbivudine monotherapy. Besides serum creatine phosphokinase, blood lactate level should also be closely monitored in patients receiving telbivudine. (C) 2013 Baishideng. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据